GlassScriptPhysician profile
Carolyn Davis
NPI 1447287172
$2,737.61
in general payments reported to CMS, 2019-2025
27 companies · $209 in 2025
The $209 reported for 2025 was more than what 75% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $374 · 2021: $537 · 2022: $473 · 2023: $618 · 2024: $223 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $448.14 | 2021-2024 | Azstarys |
| Pfizer INC. | $341.64 | 2019-2025 | |
| Tris Pharma INC | $318.41 | 2019-2023 | Dyanavel Xr |
| Cranial Technologies, INC | $245.90 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $168.70 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Neos Therapeutics, LP | $137.38 | 2019-2022 | |
| Sanofi Pasteur INC. | $133.47 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $126.76 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $117.61 | 2020-2022 | |
| Sobi, INC | $83.39 | 2020-2023 | |
| Ironshore Pharmaceuticals INC. | $80.14 | 2019-2024 | |
| Kaleo, INC. | $77.07 | 2022-2023 | Auvi-Q |
| Genentech USA, INC. | $67.31 | 2020-2022 | |
| Adlon Therapeutics L.P. | $65.46 | 2020-2021 | |
| Boston Scientific Corporation | $63.29 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhodes Pharmaceuticals L.P. | $43.14 | 2019 | |
| Collegium Pharmaceutical, INC. | $36.82 | 2025 | Jornay Pm |
| Dermira, INC. | $32.13 | 2020 | |
| Seqirus USA INC | $27.52 | 2025 | Flucelvax |
| Biomarin Pharmaceutical INC. | $20.08 | 2024 | Voxzogo 1.2mg |
| Teva Pharmaceuticals USA, INC. | $18.71 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.72 | 2021 | |
| Genzyme Corporation | $15.23 | 2023 | |
| Shire North American Group INC | $14.94 | 2019 | |
| Noven Therapeutics, LLC | $13.43 | 2023 | Xelstrym |
| Jazz Pharmaceuticals INC. | $12.39 | 2019 | |
| Glaxosmithkline, LLC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.